Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
908 Devices, Inc. (MASS)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
$10.15-8.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MASS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating income improvement | A primary condition in 908 Devices, Inc.'s published investment case. The stated target is Operating income improves from -$12.88M in 2026-Q1 toward positive. | Under Pressure | Operating income remains negative or worsens over next 4 quarters | Operating income: $-12.809M FY2026-Q2; GAAP. Published target: Operating income improves from -$12.88M in 2026-Q1 toward positive. Target period is not explicitly aligned with this observation. Aug 11, 2026-12,809,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk growth business with fragile earnings quality and current losses, rather than an established compounder. The long-term thesis is intact, supported by recent earnings beats and progress on stated operating priorities, but evidence confidence is medium.
MASS is valued at a 2.57 premium versus peers, with a small positive expectations gap of 0.06; the valuation model has low confidence. The premium appears to reflect durable growth expectations, while the evidence does not show that the full combination of expensive valuation, weak execution, and turbulence is priced in.
Near term, management’s 2026 revenue guidance implies 21% to 25% growth, and quarterly revenue rose from $13.4 million to $16.1 million. Adjusted EBITDA losses narrowed and adjusted gross margin improved, though the company remains loss-making; NIRLAB integration is progressing but still mixed. Near-term risk is elevated because earnings surprises have been erratic, and a guidance reversal or weaker employment data could add pressure.
Over the next few quarters, the thesis hinges on maintaining the recently raised guidance and continuing to narrow operating losses. NIRLAB’s market introduction and agency engagement need to translate into sustained progress. Healthcare sector momentum could help if bellwethers continue to report strong results, while weaker employment data could weigh on cyclical names.
For the 1 to 3 year view, MASS has a credible growth and operating-improvement case, but its losses, fragile earnings quality, and peer premium make execution the key test. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Revenue growth of 19% to 25% in 2026 | A primary condition in 908 Devices, Inc.'s published investment case. The stated target is >=19% YoY growth in 2026. | Intact | YoY revenue growth falls below 19% in FY26 | Revenue growth: 23.31% FY2026-Q2; GAAP. Published target: >=19% YoY growth in 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 11, 202623.314154 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “ 2026 Guidance 908 Devices updates its full year revenue guidance range to $68.0 million to $70.0 million (from $67.0 million to $70.0 million previously), raising the low end of the range and representing 21% to 25% growth compared to 2025 revenue.” “ “We delivered another strong quarter, growing revenue 23% year-over-year, while narrowing our Adjusted EBITDA loss by more than half compared to a year ago,” said Kevin J.” Delivery assessment Nov 4, 2026 |
Successful integration of NIRLAB acquisition | A supporting condition in 908 Devices, Inc.'s published investment case. The stated target is NIRLAB acquisition contributes positively to revenue and operations in FY26. | Intact | Acquisition fails to add revenue or causes operational issues in FY26 | NIRLAB integration on track; Q2 revenue growth strong NIRLAB acquisition closed May 2026. Q2 2026 results showed strong revenue growth and raised guidance, supporting successful integration. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.29 → $-0.46 · observed estimates
$0.08B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.29 | $82,369,500 | 3 / 4 |
| 2026-07-25 | $-0.31 | $82,494,500 | 2 / 3 |
| 2026-07-26 | $-0.29 | $82,369,500 | 3 / 4 |
| 2026-07-27 | $-0.29 | $82,369,500 | 3 / 4 |
| 2026-07-28 | $-0.31 | $82,494,500 | 2 / 3 |
| 2026-07-29 | $-0.29 | $82,369,500 | 3 / 4 |
| 2026-07-30 | $-0.29 | $82,369,500 | 3 / 4 |
| 2026-07-31 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-01 | $-0.32 | $82,095,600 | 2 / 3 |
| 2026-08-02 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-03 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-04 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-05 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-06 | $-0.32 | $82,095,600 | 3 / 4 |
| 2026-08-07 | $-0.32 | $82,095,600 | 3 / 4 |
| 2026-08-08 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-09 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-10 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-12 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-13 | $-0.30 | $81,995,600 | 4 / 5 |
| 2026-08-14 | $-0.32 | $82,095,600 | 3 / 4 |
| 2026-08-15 | $-0.32 | $82,095,600 | 3 / 4 |
| 2026-08-16 | $-0.32 | $82,095,600 | 3 / 4 |
| 2026-08-17 | $-0.32 | $82,095,600 | 3 / 4 |
| 2026-08-18 | $-0.32 | $82,095,600 | 3 / 4 |
| 2026-08-19 | $-0.32 | $82,095,600 | 3 / 4 |
| 2026-08-20 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-21 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-22 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-23 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-24 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-25 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-26 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-27 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-28 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-29 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-30 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-08-31 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-01 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-02 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-03 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-04 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-05 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-06 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-07 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-08 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-09 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-10 | $-0.37 | $82,644,600 | 3 / 4 |
| 2026-09-11 | $-0.45 | $82,513,917 | 3 / 5 |
| 2026-09-12 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-13 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-14 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-15 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-16 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-17 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-18 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-19 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-20 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-21 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-22 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-23 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-24 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-25 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-26 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-27 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-28 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-29 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-09-30 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-01 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-02 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-03 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-04 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-05 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-06 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-07 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-08 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-09 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-10 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-11 | $-0.45 | $82,537,167 | 3 / 5 |
| 2026-10-12 | $-0.45 | $82,537,167 | 2 / 5 |
| 2026-10-13 | $-0.45 | $82,537,167 | 2 / 5 |
| 2026-10-14 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-15 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-16 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-17 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-18 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-19 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-20 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-21 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-22 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-23 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-24 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-25 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-26 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-27 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-28 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-29 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-30 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-10-31 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-11-01 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-11-02 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-11-03 | $-0.46 | $82,537,167 | 3 / 5 |
| 2026-11-04 | $-0.46 | $82,537,167 | 3 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.